As a library, NLM provides access to scientific literature.

Inclusion in an NLM database does not

imply endorsement of, or agreement with, the contents by NLM or the National Institutes of
Health. Learn more about our disclaimer.

J Pharm Bioallied Sci. 2012 Aug; 4(Suppl 2): S310–S312. PMCID: PMC3467903
doi: 10.4103/0975-7406.100283 PMID: 23066278

Microarray and its applications

Rajeshwar Govindarajan, Jeyapradha Duraiyan,1 Karunakaran Kaliyappan, and Murugesan Palanisamy2

Abstract

Microarray is one of the most recent advances being used for cancer research; it pro-
vides assistance in pharmacological approach to treat various diseases including oral le-
sions. Microarray helps in analyzing large amount of samples which have either been
recorded previously or new samples; it even helps to test the incidence of a particular
marker in tumors. Till recently, microarray's usage in dentistry has been very limited,
but in future, as the technology becomes affordable, there may be increase in its usage.
Here, we discuss the various techniques and applications of microarray or DNA chip.

KEY WORDS: Cancer, human genome, microarray, tissue microarray

Once the human genome sequence was completed in 2001, it paved the way for many
experiments and researches; one such area was identifying the regions of DNA which
control normal and disease states. Functional genomics is the study of gene function
through parallel expression measurements of a genome. The most common tools used to
carry out these measurements include complementary DNA microarrays, oligonu-
cleotide microarrays, or serial analysis of gene expression (SAGE). Microarray analysis
can be divided into two main steps: probe production and target (cDNA) production.
Specific sequences are immobilized to a surface and reacted with labeled cDNA targets.
A signal resulting from hybridization of the labeled target with the specific immobilized
probe identifies which RNAs are present in the unknown target sample.

Prevention, diagnosis, and treatment in dental practice are based on an understanding

of the biology of underlying oral health and disease. Few aspects of patient care will re-
main untouched by today's rapid advances in biological research. In the future, dentists
may use inexpensive but remarkably sophisticated diagnostic tests to diagnose infection,
oral lesions, and symptoms of temporomandibular dysfunction (TMD). The small varia-
tions in the DNA sequence that lead to different characteristics (such as skin color, facial
features, or height) are known as polymorphisms, which also can cause or contribute to
the development of many syndromes and diseases.[1] These genetic variations can be
easily identified by the microarray technique.

Microarray provides a basis to genotype thousands of different loci at a time, which is

useful for association and linkage studies to isolate chromosomal regions related to a
particular disease. This array also can be used to locate chromosomal aberrations re-
lated to cancer, such as segments of allelic imbalance, which can be identified by loss of
heterozygosity.[2] By comparative genomic hybridization techniques on genomic DNA,
amplified or deleted regions in the chromosomes can be identified, such as in the case of
oral cancer.[3]

Technique

Gene microarray technology rests on the ability to deposit many (tens of thousands) dif-
ferent DNA sequences on a small surface, usually a glass slide (often referred to as a
“chip”). The different DNA fragments are arranged in rows and columns such that the
identity of each fragment is known through its location on the array. Two types of mi-
croarrays are gene expression microarray and tissue microarray (TMA). Techniques like
Northern blot and reverse transcriptase-polymerase chain reaction (RT-PCR) allow test-
ing for only a few genes per experiment. But microarray or “global expression profiling”
not only looks at orders of magnitude more genes than was possible previously, but also
has the advantage that the genes examined are not influenced by preselection of genes.

Microarray Principle

mRNA is an intermediary molecule which carries the genetic information from the cell
nucleus to the cytoplasm for protein synthesis. Whenever some genes are expressed or
are in their active state, many copies of mRNA corresponding to the particular genes are
produced by a process called transcription. These mRNAs synthesize the corresponding
protein by translation. So, indirectly by assessing the various mRNAs, we can assess the
genetic information or the gene expression. This helps in the understanding of various
processes behind every altered genetic expression. Thus, mRNA acts as a surrogate
marker. Since mRNA is degraded easily, it is necessary to convert it into a more stable
cDNA form. Labeling of cDNA is done by fluorochrome dyes Cy3 (green) and Cy5 (red).
The principle behind microarrays is that complementary sequences will bind to each
other.

The unknown DNA molecules are cut into fragments by restriction endonucleases; fluo-
rescent markers are attached to these DNA fragments. These are then allowed to react
with probes of the DNA chip. Then the target DNA fragments along with complementary
sequences bind to the DNA probes. The remaining DNA fragments are washed away. The
target DNA pieces can be identified by their fluorescence emission by passing a laser
beam. A computer is used to record the pattern of fluorescence emission and DNA identi-
fication. This technique of employing DNA chips is very rapid, besides being sensitive
and specific for the identification of several DNA fragments simultaneously.

The study of the expression of most, if not all, genes in a specimen is not hypothesis-
driven as most of the studies used to be,[4] but is instead referred to as “discovery-type
research” or in a less flattering description as “fishing expeditions.” Whereas cDNA de-
rived from a tumor is hybridized to a chip to study gene expression levels, alterations in
DNA copy number (gene amplification or deletion) can be measured by hybridizing fluo-
rescently labeled DNA from a tumor specimen to these chips.[5,6] TMAs are constructed
by transferring cores of paraffin-embedded tissue to pre-cored holes in a recipient paraf-
fin block.[7] Over 500 cores can be placed in a single block by this technique. Sections cut
from TMA blocks can then be used for immunohistochemistry (IHC) or in situ hybridiza-
tion studies. TMAs are similar to gene expression microarrays in having samples arrayed
in rows and columns on a glass slide; they differ in that each element on the TMA slide
corresponds to a single patient sample, allowing multiple patient samples to be assessed
for a single molecular marker in one experiment, while gene expression arrays allow as-
sessment of thousands of molecular markers on a single patient sample per experiment.

Applications

In cancer

Tumor formation involves simultaneous changes in hundreds of cells and variations in

genes. Microarray can be a boon to researchers as it provides a platform for simultane-
ous testing of a large set of genetic samples. It helps especially in the identification of sin-
gle-nucleotide polymorphisms (SNPs) and mutations, classification of tumors, identifica-
tion of target genes of tumor suppressors, identification of cancer biomarkers, identifica-
tion of genes associated with chemoresistance, and drug discovery. For example, we can
compare the different patterns of gene expression levels between a group of cancer pa-
tients and a group of normal patients and identify the gene associated with that particu-
lar cancer.

Gene microarrays have been used for comparative genomic hybridization. In this tech-
nique, genomic DNA is fluorescently labeled and used to determine the presence of gene
loss or amplification.[6,8,9] Array-based comparative genomic hybridization (aCGH) has
been used to map genetic abnormalities in a wide range of tumors, including breast car-
cinoma,[9] bladder carcinoma,[10] fallopian tube carcinoma,[11] gastric carcinoma,[12]
melanoma,[13] and lymphoma.[14] Gene expression data can identify groups of cases
with significantly different outcomes where routine histopathologic examination does
not permit subclassification.
The conversion of a non-invasive tumor to an invasive tumor also warrants research.
Clark et al. studied the gene profile of melanoma cells which became metastatic, and
found a gene, RhoC, to be expressed more in metastatic cells than in non-metastatic
melanoma cells. Microarray-based expression profiling allows us to identity families of
genes as well as the important molecular and cellular events that might be important in
complex processes like metastasis. Practical applications in future include diagnostic and
prognostic management of patients. Clinicians will be able to use microarrays during
early clinical trials to confirm the mechanisms of action of drugs and to assess drug sen-
sitivity and toxicity. They can be used to develop a new molecular taxonomy of cancer,
including clustering of cancers according to prognostic groups on the basis of gene ex-
pression profiles.[15] Areas that can be coupled with microarray technologies include
classification of diseases, or molecular phenotyping; the study of gene function in rela-
tion to gene regulatory networks, or functional genomics; pharmacogenomics and devel-
opmental biology.

Antibiotic treatment

Increase in the number of resistant bacteria and superadded infections has led to failure
of antibiotics. Virulence of the bacterial strains too affects the outcome of the disease
process. In oral cavity where anaerobic bacteria might be the infective agent, they often
are not easily culturable, especially organisms such as actinomyces. DNA microarray
analysis helps as the bacterial genomic DNA often outlasts the viability of the bacteria
and a diagnosis can be made using a small amount of DNA, as opposed to the large num-
bers of bacteria needed for culture. In future, an abscess specimen might be sent not for
culture and sensitivity testing, but rather for DNA microarray analysis.

Early detection of oral precancerous lesions

Leukoplakia or white lesions of the oral cavity may result from a myriad of reversible
conditions. Currently, microscopic examination fails to identify the small subset of these
lesions that progress to oral cancer. Identification of gene expression profiles or “ge-
nomic fingerprints” will allow clinicians to differentiate harmless white lesions from
precancerous lesions or from very early cancer. Recent studies have illustrated the effec-
tiveness of microarrays in oral cancer.[16,17] In future, samples taken from an incisional
biopsy or brush biopsy may be sent to a laboratory for gene expression analysis. Early
diagnosis and management of oral cancer is correlated with increased survival.
Identification and treatment of premalignant and early cancerous oral lesions may be-
come one of the most valuable services in future performs.

Conclusion

This review has given a small outline of the technique behind microarray and the vari-
ous steps involved. The technique, though limited at present in its applications due to the
cost factor, may widen its prospects once there is increase in the availability of commer-
cial products. The ability to record large number of old samples and analyzing them for
various genetic alterations helps in understanding the concept of molecular biology.
Microarrays hold much promise for the analysis of diseases in the oral cavity.
Classifications of oral disease by DNA, RNA, or protein profiles will greatly enhance our
ability to diagnose, prevent, monitor and treat our patients. Currently, microarrays are
primarily a research tool. Microarrays promise a more biologically based, individual-
ized, and vastly improved standard for oral care, which will have great clinical impact
on the way dentistry will be practiced in the future.

Footnotes

Source of Support: Nil

Conflict of Interest: None declared.

References

1. Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, et al. Large-scale identification, mapping, and
genotyping of single-nucleotide polymorphisms in the human genome. Science. 1998;280:1077–82. [PubMed]
[Google Scholar]

2. Lindblad-Toh K, Tanenbaum DM, Daly MJ, Winchester E, Lui WO, Villapakkam A, et al. Loss of heterozygosity
analysis of small-cell lung carcinomas using single nucleotide polymorphism arrays. Nat Biotechnol.
2000;18:1001–5. [PubMed] [Google Scholar]

3. Jiang WW, Fujii H, Shirai T, Mega H, Takagi M. Accumulative increase of loss of heterozygosity from
leukoplakia to foci of early cancerization in leukoplakia of the oral cavity. Cancer. 2001;92:2349–56. [PubMed]
[Google Scholar]

4. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet. 1999;21:33–
7. [PubMed] [Google Scholar]

5. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, et al. High resolution analysis of DNA copy number
variation using comparative genomic hybridization to microarrays. Nat Genet. 1998;20:207–11. [PubMed]
[Google Scholar]

6. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, et al. Genome-wide analysis
of DNA copy-number changes using cDNA microarrays. Nat Genet. 1999;23:41–6. [PubMed] [Google Scholar]

7. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-
throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–7. [PubMed] [Google Scholar]

8. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, et al. Microarray analysis reveals a major
direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl
Acad Sci U S A. 2002;99:12936–68. [PMC free article] [PubMed] [Google Scholar]

9. SolinasToldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Döhner H, et al. Matrix-basedcomparative

genomic hybridization: Biochips to screen for genomic imbalances. Genes Chromosomes Cancer. 1997;20:399–
407. [PubMed] [Google Scholar]
10. Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S, et al. Array-based comparative
genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res.
2003;63:2872–80. [PubMed] [Google Scholar]

11. Snijders AM, Nowee ME, Fridlyand J, Piek JM, Dorsman JC, Jain AN, et al. Genome-wide arraybased
comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases
encompassing CCNE1 in fallopian tube carcinoma. Oncogene. 2003;22:4281–6. [PubMed] [Google Scholar]

12. Weiss MM, Snijders AM, Kuipers EJ, Ylstra B, Pinkel D, Meuwissen SG, et al. Determination of amplicon
boundaries at 20q13.2 in tissue samples of human gastric adenocarcinomas by high-resolution microarray
comparative genomic hybridization. J Pathol. 2003;200:320–6. [PubMed] [Google Scholar]

13. Buckley PG, Mantripragada KK, Benetkiewicz M, Tapia-Páez I, Diaz De Ståhl T, Rosenquist M, et al. A
fullcoverage, high-resolution human chromosome 22 genomic microarray for clinical and research
applications. Hum Mol Genet. 2002;11:3221–9. [PubMed] [Google Scholar]

14. Martinez-Climent JA, Alizadeh AA, Segraves R, Blesa D, Rubio-Moscardo F, Albertson DG, et al.
Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set
of DNA copy number and gene expression alterations. Blood. 2003;101:3109–17. [PubMed] [Google Scholar]

15. Pascale F, Macgregor, Jeremy A. Squire, Application of microarrays to the analysis of gene expression in
cancer. Clin Chem. 2002;48:1170–7. [PubMed] [Google Scholar]

16. Alevizos I, Mahadevappa M, Zhang X. Oral cancer in vivo gene expression profiling assisted by laser capture
microdissection and microarray analysis. Oncogene. 2001;20:6196–204. [PubMed] [Google Scholar]

17. Kuo WP, Jenssen TK, Park PJ, Lingen MW, Hasina R, Machado LO. Gene expression levels in different stages
of progression in oral squamous cell carcinoma. Proc AMIA Symp. 2002. pp. 415–9. [Available on
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2244435/ ] [PMC free article] [PubMed]